<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318354</url>
  </required_header>
  <id_info>
    <org_study_id>OLME/10/026</org_study_id>
    <nct_id>NCT03318354</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablet Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Olmesartan Medoxomil Tablets 40 mg [Torrent,India] Versus Benicar 40 mg Tablets [Daiichi Sankyo Inc., USA] in Healthy Subjects-Fasted Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets&#xD;
      40 mg and Benicar 40 mg Tablets of Daichi Sankyo Inc. USA. Dosing periods of studies were&#xD;
      separated by a washout period of 7 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open Label, Randomized, 2-period, 2- Treatment, 2-Sequence, Crossover, Single-dose&#xD;
      Bioequivalence Study of Olmesartan Medoxomil Tablets containing Olmesartan Medoxomil 40 mg&#xD;
      (Test Formulation, Torrent Pharmaceutical Ltd., India) Versus Benicar® 40 mg Tablets&#xD;
      containing Olmesartan Medoxomil 40 mg (Reference, Daiichi Sankyo Inc.,USA) in Healthy Human&#xD;
      Volunteers Under Fasting Condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Pre dose to 72 hours post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Pre dose to 72 hours post dose.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Torrent's Olmesartan Medoxomil Tablets 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daiichi Sankyo Inc's Benicar Tablets 40 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torrent's Olmesartan Medoxomil Tablets 40 mg</intervention_name>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daiichi Sankyo Inc's Benicar Tablets 40 mg</intervention_name>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males with age between 18-45 years (both inclusive)&#xD;
&#xD;
          -  Weight equal to or more than 50.00 Kgs&#xD;
&#xD;
          -  BMI 18.50 - 24.90 Kg/m2&#xD;
&#xD;
          -  Healthy as determined by medical history, clinical and laboratory examination&#xD;
             performed within 21 days prior to admission day for the first period of the study.&#xD;
&#xD;
          -  Must have provided written informed consent for participation in the study in the&#xD;
             subject's vernacular language&#xD;
&#xD;
          -  In the opinion of the Principal Investigator/Designee, be able to comply with the&#xD;
             study procedures and protocol restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or idiosyncratic reaction to Olmesartan, its excipients or&#xD;
             similar classes of drugs&#xD;
&#xD;
          -  Any evidence of significant abnormalities upon physical or clinical examination&#xD;
&#xD;
          -  Sitting blood pressure less than 100/70 mm Hg or more than 140/90 mm Hg and radical&#xD;
             pulse rate less than 60 mm Hg or more than 100 mm Hg per minute at the time of&#xD;
             screening.&#xD;
&#xD;
          -  Laboratory values, which are significantly different from predefined reference ranges&#xD;
             and judged clinically significant.&#xD;
&#xD;
          -  Any clinically significant abnormality in ECG.&#xD;
&#xD;
          -  Any clinically significant abnormality in Chest X-ray (PA view)&#xD;
&#xD;
          -  Regular use of tobacco or nicotine in significant amount in any form (e.g. use of more&#xD;
             than 10 cigarettes a day) or have difficulty in abstaining from [smoking] nicotine use&#xD;
             for the duration of the study period.&#xD;
&#xD;
          -  History of drug dependence or excessive alcohol intake [subjects who drink more than 2&#xD;
             units per day (30 ml of 40% alcohol) or more than 14 units per week] on a habitual&#xD;
             basis, or inability to abstain from alcohol for the duration of study period.&#xD;
&#xD;
          -  History or presence of serious gastrointestinal, liver, kidney, heart, lung,&#xD;
             neurological or blood disease, diabetes or glaucoma.&#xD;
&#xD;
          -  History or presence of any chronic illnesses such as arthritis, asthma, epilepsy,&#xD;
             hypertension etc.&#xD;
&#xD;
          -  Presence of disease markers of HIV 1 OR 2, Hepatitis B or C Viruses and VDRL.&#xD;
&#xD;
          -  Positive result for drug(s) of abuse testing (amphetamines, barbiturates,&#xD;
             benzodiazepines, cannabinoids, cocaine and opioids) in urine.&#xD;
&#xD;
          -  Positive test for alcohol breath analyzer test.&#xD;
&#xD;
          -  History and presence of any psychiatric illness.&#xD;
&#xD;
          -  History and presence of any illness including allergic skin diseases, allergic asthma&#xD;
             and drug-induced allergy, e.g. NSAIDs&#xD;
&#xD;
          -  History of significant blood loss (≥ 350 mL) due to any reason, including blood&#xD;
             donation within last 12 weeks prior to screening.&#xD;
&#xD;
          -  Existence of any surgical or medical condition which in the judgment of Principal&#xD;
             Investigator/ Designee might interfere with the absorption, distribution, metabolism&#xD;
             or excretion of the study drug, or, is likely to compromise the safety of subject.&#xD;
&#xD;
          -  Intake of any enzyme-modifying drugs such as cimetidine, theophylline,&#xD;
             benzodiazepines, ranitidine, proton pump inhibitors, erythromycin, diuretics,&#xD;
             ketoconazole, anti hypertensive drugs, dopamine agonists, etc within 30 days of study&#xD;
             drug administration, or administration/ intake of any prescription or OTC drug&#xD;
             including vitamins and natural supplements within 30 days of study drug&#xD;
             administration. In such cases, enrolment of the subject in the study will be at the&#xD;
             discretion of the Principal Investigator/designee.&#xD;
&#xD;
          -  Intake of unusual diet (e.g. low sodium) for two weeks prior to screening and&#xD;
             throughout the subject's participation the study. In such case, subject selection will&#xD;
             be at the discretion of the Principal investigator/ designee.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 19, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

